Regeneron Pharmaceuticals, Inc. (REGN) — Financial statements
Income statement, balance sheet, and cash flow for Regeneron Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 14,343↑1.0% | 14,202↑8.3% | 13,117↑7.8% | 12,173↓24.3% | 16,072 | |
| Cost of Revenue | 2,101↑6.6% | 1,971↓12.2% | 2,245↑31.6% | 1,705↓37.4% | 2,724 | |
| Gross Profit | 12,242↑0.1% | 12,232↑12.5% | 10,873↑3.9% | 10,468↓21.6% | 13,348 | |
| Operating Expenses | ||||||
| R&D Expenses | 5,850↑11.8% | 5,233↑31.3% | 3,987↑30.5% | 3,056↑16.6% | 2,622 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 2,700↓8.6% | 2,954↑16.3% | 2,540↑20.0% | 2,116↑15.9% | 1,825 | |
| Other Expenses | 114↑113.7% | 53↑2642.9% | -2↑97.7% | -90↓97.1% | -46 | |
| Operating Expenses | 8,664↑5.1% | 8,241↑26.3% | 6,524↑28.4% | 5,082↑15.5% | 4,401 | |
| Total Costs & Expenses | 10,765↑5.4% | 10,211↑16.5% | 8,769↑29.2% | 6,787↓4.7% | 7,125 | |
| Operating Results | ||||||
| Operating Income | 3,578↓10.3% | 3,991↓8.2% | 4,349↓19.3% | 5,386↓39.8% | 8,947 | |
| Depreciation & Amortization | 544↑12.6% | 483↑14.7% | 421↑23.3% | 341↑19.3% | 286 | |
| EBITDA | 5,818↑9.4% | 5,318↑13.3% | 4,693↓10.8% | 5,260↓45.6% | 9,669 | |
| EBIT | 5,275↑9.1% | 4,835↑13.2% | 4,272↓13.1% | 4,918↓47.6% | 9,383 | |
| Interest & Other Income | ||||||
| Net Interest Income | 673↑2.6% | 656↑55.2% | 423↑320.0% | 101↑275.7% | -57 | |
| Interest Income | 717↑0.8% | 711↑43.5% | 496↑209.7% | 160 | 0.00 | |
| Interest Expense | 44↓20.7% | 55↓24.4% | 73↑22.9% | 59↑3.7% | 57 | |
| Non-Operating Income | -1,697↓100.9% | -844↓1206.7% | 76↓83.7% | 467↑207.1% | -436 | |
| Other Income / Expenses | 1,653↑109.4% | 789↑628.6% | -149↑71.7% | -527↓239.0% | 379 | |
| Income Before Tax | 5,231↑9.4% | 4,780↑13.8% | 4,199↓13.6% | 4,859↓47.9% | 9,326 | |
| Income Tax Expense | 726↑97.6% | 367↑49.5% | 246↓52.8% | 520↓58.4% | 1,251 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 4,505↑2.1% | 4,413↑11.6% | 3,954↓8.9% | 4,338↓46.3% | 8,075 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 4,505↑2.1% | 4,413↑11.6% | 3,954↓8.9% | 4,338↓46.3% | 8,075 | |
| Bottom-Line Net Income | 4,505↑2.1% | 4,413↑11.6% | 3,954↓8.9% | 4,338↓46.3% | 8,075 | |
| EPS (Basic) | 43.07↑5.3% | 40.90↑10.4% | 37.05↓8.5% | 40.51↓47.0% | 76.40 | |
| EPS (Diluted) | 41.48↑8.2% | 38.34↑10.3% | 34.77↓9.0% | 38.22↓46.9% | 71.97 | |
| Weighted Average Shares | 105↓3.1% | 108↑1.1% | 107↓0.4% | 107↑1.3% | 106 | |
| Weighted Average Diluted Shares | 109↓5.6% | 115↑1.2% | 114↑0.2% | 114↑1.2% | 112 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.